US EditionSemaglutide Patent Expiry Opens Door To GLP-1 Generics In Canada - Data Intelligence
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Semaglutide Patent Expiry Opens Door To GLP-1 Generics In Canada - Data Intelligence
Newsletter Signup – Under Article / In Page “*” indicates required fields In 2020, Novo Nordisk’s Canadian patent for semaglutide, the active ingredient in its blockbuster GLP-1 drugs Ozempic and Wegovy, quietly expired. The reason? A small missed maintenance fee, reportedly around 1,200 Canadian dollars. The lapse went largely unnoticed until it was recently highlighted by Derek Lowe in Science, where he described it as an eyebrow-raising mome…
Did Novo open the Canadian market to GLP-1 generics?
Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a small fee? The post Did Novo open the Canadian market to GLP-1 generics? appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, pro…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
